Details of the Drug

General Information of Drug (ID: DMYQCWT)

Drug Name
Tecartus
Synonyms Brexucabtagene autoleucel; KTE-X19
Indication
Disease Entry ICD 11 Status REF
Mantle cell lymphoma 2A85.5 Approved [1]
Affected Organisms
Humans and other mammals
ATC Code
L01XL06: Tecartus
L01XL: Antineoplastic cell and gene therapy
L01X: OTHER ANTINEOPLASTIC AGENTS
L01: ANTINEOPLASTIC AGENTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Drug Type
CAR T Cell Therapy
ADMET Property
Absorption Tmax
The time to maximum plasma concentration (Tmax) is 7-15 days [2]
Cross-matching ID
UNII
4MD2J2T8SJ
DrugBank ID
DB15699
TTD ID
D18SHN

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B-lymphocyte surface antigen B4 (CD19) TTW640A CD19_HUMAN Not Available [1]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Mantle cell lymphoma
ICD Disease Classification 2A85.5
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
B-lymphocyte surface antigen B4 (CD19) DTT CD19 2.33E-24 -1.06 -1.33
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
2 FDA Approved Drug Products: Tecartus (brexucabtagene autoleucel) suspension